Discontinuation of glucagon-like peptide-1 receptor agonists among US adults: A national survey

BACKGROUND: Although many people discontinue glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the reasons for discontinuation are unclear. OBJECTIVE: To identify self-reported reasons for GLP-1 RA discontinuation among US adults. METHODS: Cross-sectional survey of US adults fielded in June 2025 using Ipsos Omnibus and incorporating survey weights calibrated to census benchmarks. We included individuals who initiated a GLP-1 RA between January 2022 and June 2025 and subsequently discontinued therapy. Outcomes included duration of use, self-reported reason(s) for discontinuation, medication source, out-of-pocket payment, and insurance coverage. Descriptive statistics and chi-square tests for statistical significance were used. RESULTS: = 0.009). Neither diabetes status nor GLP-1 RA source was significantly associated with early discontinuation (<6 months). CONCLUSIONS: In this national survey, most US adults who stopped GLP-1 RAs did so within 6 months because of cost, adverse effects, lack of coverage, or having achieved a weight loss goal. Differences in coverage, costs, and sourcing are modifiable targets that may decrease high rates of GLP-1 RA discontinuation.